NASDAQ:TTOOT2 Biosystems Stock Price, Forecast & News

$1.31

+0.13 (+11.02 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.15

Now: $1.31▼

$1.34

50-Day Range

$0.51

MA: $0.65▼

$1.30

52-Week Range

$0.24

Now: $1.31▼

$3.21

Volume10.83 million shs

Average Volume16.34 million shs

Market Capitalization$156.11 million

P/E RatioN/A

Dividend YieldN/A

Beta1.08

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
T2 Biosystems has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.28, T2 Biosystems has a potential upside of 226.7% from its current price of $1.31.
Amount of Analyst Coverage
T2 Biosystems has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
T2 Biosystems has received 375 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
T2 Biosystems has received 297 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
T2 Biosystems has received 55.80% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote “Outperform” if you believe TTOO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
T2 Biosystems does not currently pay a dividend.
Dividend Growth
T2 Biosystems does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, T2 Biosystems insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 30.30% of the stock of T2 Biosystems is held by insiders.
Percentage Held by Institutions
Only 9.61% of the stock of T2 Biosystems is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for T2 Biosystems are expected to grow in the coming year, from ($0.72) to ($0.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of T2 Biosystems is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of T2 Biosystems is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.34 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TTOO

Previous Symbol

CUSIPN/A

CIK1492674

Webwww.t2biosystems.com

Phone781-761-4646

Debt

Debt-to-Equity RatioN/A

Current Ratio0.76

Quick Ratio0.70

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$8.34 million

Price / Sales18.72

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.73) per share

Price / Book-1.79

Profitability

EPS (Most Recent Fiscal Year)($1.30)

Net Income$-59,010,000.00

Net Margins-645.05%

Return on EquityN/A

Return on Assets-147.85%

Miscellaneous

Employees151

Outstanding Shares119,170,000

Market Cap$156.11 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for TTOO and its competitors with MarketBeat's FREE daily newsletter.

T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

How has T2 Biosystems' stock been impacted by COVID-19 (Coronavirus)?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTOO shares have increased by 164.6% and is now trading at $1.31. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of T2 Biosystems?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for T2 Biosystems.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for T2 Biosystems.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems Inc (NASDAQ:TTOO) issued its quarterly earnings results on Tuesday, May, 5th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.06. The medical equipment provider had revenue of $2.55 million for the quarter. View T2 Biosystems' earnings history.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its first quarter 2020 After-Hours earnings guidance on Tuesday, March, 24th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.2-2.6 million, compared to the consensus revenue estimate of $3.11 million.

What price target have analysts set for TTOO?

6 analysts have issued 12-month price targets for T2 Biosystems' stock. Their forecasts range from $0.40 to $10.00. On average, they anticipate T2 Biosystems' share price to reach $4.28 in the next twelve months. This suggests a possible upside of 226.7% from the stock's current price. View analysts' price targets for T2 Biosystems.

What are Wall Street analysts saying about T2 Biosystems stock?

Here are some recent quotes from research analysts about T2 Biosystems stock:

1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (5/9/2020)
2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)

Has T2 Biosystems been receiving favorable news coverage?

News headlines about TTOO stock have been trending positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. T2 Biosystems earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutT2 Biosystems.

Who are some of T2 Biosystems' key competitors?

Some companies that are related to T2 Biosystems include SurModics (SRDX), LeMaitre Vascular (LMAT), SI-Bone (SIBN), Anika Therapeutics (ANIK), Antares Pharma (ATRS), Co-Diagnostics (CODX), Repro Med Systems (KRMD), Repro-Med Systems (REPR), AngioDynamics (ANGO), MiMedx Group (MDXG), Utah Medical Products (UTMD), Intersect ENT (XENT), Alphatec (ATEC), Cytosorbents (CTSO) and SeaSpine (SPNE). View all competitors.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include SCYNEXIS (SCYX), Verastem (VSTM), Tonix Pharmaceuticals (TNXP), Opko Health (OPK), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Zynerba Pharmaceuticals (ZYNE).

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:

Prof. Michael J. Cima, Co-Founder & Independent Director (Age 60, Pay $62.5k)
Mr. Alec Barclay, Sr. VP of Operations (Age 39, Pay $477.4k)
Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 41, Pay $473.93k)
Mr. John J. Sperzel III, Pres, CEO & Director (Age 56)
Dr. Tyler E. Jacks, Co-Founder (Age 59)

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.64%), Gagnon Securities LLC (1.11%), GSA Capital Partners LLP (0.31%), Ironwood Financial llc (0.30%) and UBS Group AG (0.22%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View institutional ownership trends for T2 Biosystems.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, GSA Capital Partners LLP, Gagnon Securities LLC, Ironwood Financial llc, and UBS Group AG. View insider buying and selling activity for T2 Biosystems.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $1.31.

How big of a company is T2 Biosystems?

T2 Biosystems has a market capitalization of $156.11 million and generates $8.34 million in revenue each year. The medical equipment provider earns $-59,010,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. T2 Biosystems employs 151 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff